Strategic Forecast for the Recombinant DNA Technology Industry: Market Outlook 2025-2034

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Recombinant DNA Technology Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a significant increase in the market size of recombinant DNA technology. Its growth is projected to escalate from $858.94 billion in 2024 to $920.82 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.2%. The historic growth pattern has been influenced by factors such as the demand in healare, growth in the biopharmaceutical industry, surge in research and development investments, and the advent of personalized medicine.

How Will the Recombinant DNA Technology Market Size Evolve and Grow by 2029?
The market scope for recombinant DNA technology is anticipated to witness substantial growth in the coming years. It is projected to expand to $1318.72 billion in 2029, with a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period is attributed to the increase in chronic diseases, the rise of biotech startups, enhanced biotech funding, the global spread of biotech markets, consumer receptiveness, and education. Noteworthy trends during the forecast period include breakthroughs in science and gene editing, cell and gene therapies, the emergence of RNA therapeutics, therapeutic applications for rare diseases, and the incorporation of artificial intelligence and data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

What Drivers Are Propelling the Growth of Recombinant DNA Technology Market Forward?
The surge in chronic illnesses is anticipated to fuel the expansion of the recombinant DNA technology market. These diseases, typically persisting for a year or longer and often require ongoing medical attention or limit daily tasks, or both. Recombinant DNA technology has elicited medical advancements by developing biopharmaceutical proteins for pharmaceutical use and swapping out faulty genes with healthy ones via gene therapy, targeting disease cures. For example, the World Health Organization, a Switzerland-based intergovernmental body, predicted in February 2024 that by 2050, over 35 million new cancer cases would emerge, marking a 77% rise compared to the approximate 20 million cases in 2022. Hence, the swollen number of chronic illnesses is a critical factor propelling the recombinant DNA technology market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Emerging Trends Are Transforming the Recombinant DNA Technology Market in 2025?
In the recombinant DNA technology market, one prominent trend is the progression of technology. Leading businesses in this market are emphasizing on advancements in order to maintain their market status. An illustrative example of this is when Bluebird bio, Inc., a biotechnology firm based in the United States, launched the U.S. FDA (Food and Drug Administration) approved ZYNTEGLO in August 2022. This therapy, administered just once, treats beta-thalassemia by addressing its genetic root, enabling patients to be free from constant red blood cell transfusions. This treatment utilizes an ex-vivo lentiviral vector to alter patient cells, making it the first gene therapy for beta-thalassemia to be approved by the FDA in the United States. Undoubtedly, this leap forward eases the relentless management of beta-thalassemia for patients.

What Are the Key Segments in the Recombinant DNA Technology Market?
The recombinant DNA technology market covered in this report is segmented -

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:
1) By Recombinant Protein Drugs: Hormones, Growth Factors
2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Who Are the Key Players Shaping the Recombinant DNA Technology Market's Competitive Landscape?
Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton inson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

What Geographic Markets Are Powering Growth in the Recombinant DNA Technology Market?
North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8233

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.